Anavex to Present at SeeThruEquity Investor Conference in New York City

Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease

Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to Market

Anavex Supports Alzheimer’s Foundation of America’s 3rd Annual Concepts in Care Educational Conference

Anavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference

Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer’s Clinical Trial

Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor

Anavex Reports Fiscal Third Quarter 2014 Financial Results

Anavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations

Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies